MX2014010537A - Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas. - Google Patents

Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.

Info

Publication number
MX2014010537A
MX2014010537A MX2014010537A MX2014010537A MX2014010537A MX 2014010537 A MX2014010537 A MX 2014010537A MX 2014010537 A MX2014010537 A MX 2014010537A MX 2014010537 A MX2014010537 A MX 2014010537A MX 2014010537 A MX2014010537 A MX 2014010537A
Authority
MX
Mexico
Prior art keywords
modulators
lxr
disorders
liver
receptor
Prior art date
Application number
MX2014010537A
Other languages
English (en)
Other versions
MX361349B (es
Inventor
Raju Mohan
Original Assignee
Alexar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexar Therapeutics Inc filed Critical Alexar Therapeutics Inc
Publication of MX2014010537A publication Critical patent/MX2014010537A/es
Publication of MX361349B publication Critical patent/MX361349B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

En la presente se describen moduladores del receptor X hepático (LXR) y métodos para utilizar los moduladores de LXR en el tratamiento de enfermedades, trastornos o condiciones dérmicas. En la presente también se describen composiciones farmacéuticas que contienen dichos compuestos.
MX2014010537A 2012-03-02 2013-02-28 Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas. MX361349B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606160P 2012-03-02 2012-03-02
PCT/US2013/028438 WO2013130892A1 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Publications (2)

Publication Number Publication Date
MX2014010537A true MX2014010537A (es) 2015-03-09
MX361349B MX361349B (es) 2018-12-04

Family

ID=49083313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010537A MX361349B (es) 2012-03-02 2013-02-28 Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.

Country Status (25)

Country Link
US (5) US8987318B2 (es)
EP (2) EP3441390A1 (es)
JP (2) JP6378630B2 (es)
KR (1) KR102112879B1 (es)
CN (1) CN104284893B (es)
AU (1) AU2013225840B2 (es)
BR (1) BR112014021515A2 (es)
CA (1) CA2866113C (es)
CY (1) CY1120742T1 (es)
DK (1) DK2820013T3 (es)
ES (1) ES2691079T3 (es)
HK (1) HK1206030A1 (es)
HR (1) HRP20181623T1 (es)
HU (1) HUE040231T2 (es)
IL (1) IL234413B (es)
LT (1) LT2820013T (es)
MX (1) MX361349B (es)
NZ (1) NZ629636A (es)
PL (1) PL2820013T3 (es)
PT (1) PT2820013T (es)
RS (1) RS57863B9 (es)
SG (2) SG11201405378VA (es)
SI (1) SI2820013T1 (es)
TR (1) TR201815013T4 (es)
WO (1) WO2013130892A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820013T3 (en) 2012-03-02 2018-10-29 Ralexar Therapeutics Inc Liver X Receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
ES2694001T3 (es) * 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
CA2923178A1 (en) * 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
SI3041835T1 (sl) 2013-09-04 2020-09-30 Ellora Therapeutics, Inc. Modulatorji jetrnih X receptorjev (LXR)
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
EP3397258A2 (en) 2015-12-30 2018-11-07 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (CONICET) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
WO2021009664A1 (en) 2019-07-15 2021-01-21 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1199771A (en) * 1915-07-01 1916-10-03 Bates Valve Bag Co Wire-twisting machine.
AU2002211216A1 (en) 2000-09-18 2002-04-02 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP2005527624A (ja) 2002-05-24 2005-09-15 ファーマシア コーポレイション スルホン肝ｘ受容体調節因子
MXPA04011691A (es) 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
AU2003301020A1 (en) 2002-12-20 2004-07-22 Sankyo Company, Limited Isoquinolinone derivatives and their use as therapeutic agents
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
WO2006003923A1 (ja) 2004-06-30 2006-01-12 Sankyo Company, Limited 置換ベンゼン化合物
CN101213194A (zh) 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CN101248048B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 吡唑基lxr调节剂
AU2006261845C1 (en) 2005-06-27 2013-05-16 Exelixis Patent Company Llc Imidazole based LXR modulators
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1948636A2 (en) 2005-11-14 2008-07-30 Irm Llc Compounds and compositions as lxr modulators
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
AU2007333194A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
WO2008104077A1 (en) * 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
EP2142517A2 (en) 2007-05-18 2010-01-13 Wyeth Quinazoline compounds
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
RU2454412C2 (ru) 2007-08-13 2012-06-27 Ф.Хоффманн-Ля Рош Аг Новые пиперазинамидные производные
AU2008345681A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-a] pyridine compounds
BRPI0821315A2 (pt) 2007-12-21 2019-09-24 Wyeth Llc compostos benzimidazol
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
CA2741537A1 (en) 2008-11-07 2010-05-14 Wyeth Llc Quinoxaline-based lxr modulators
EP2367801A1 (en) 2008-11-19 2011-09-28 Wyeth LLC Polar quinazolines as liver x receptors ( lxrs ) modulators
AR074701A1 (es) 2008-12-22 2011-02-02 Schering Corp Moduladores de gamma secretasa
US20120058133A1 (en) * 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CN102648184B (zh) 2009-05-28 2015-09-30 埃克塞利希斯专利有限责任公司 Lxr调节剂
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
WO2012020820A1 (ja) * 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
MX337711B (es) * 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
DK2820013T3 (en) 2012-03-02 2018-10-29 Ralexar Therapeutics Inc Liver X Receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
JP6320382B2 (ja) 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
SI3041835T1 (sl) 2013-09-04 2020-09-30 Ellora Therapeutics, Inc. Modulatorji jetrnih X receptorjev (LXR)
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Also Published As

Publication number Publication date
US20180370959A1 (en) 2018-12-27
EP2820013A4 (en) 2015-11-11
JP6378630B2 (ja) 2018-08-22
JP2018184467A (ja) 2018-11-22
PT2820013T (pt) 2018-10-25
CA2866113A1 (en) 2013-09-06
NZ629636A (en) 2017-02-24
HRP20181623T1 (hr) 2018-12-14
RS57863B9 (sr) 2019-10-31
US20210101895A1 (en) 2021-04-08
US20170334897A1 (en) 2017-11-23
US9637481B2 (en) 2017-05-02
SG10201607345YA (en) 2016-11-29
ES2691079T9 (es) 2019-02-08
PL2820013T3 (pl) 2019-01-31
AU2013225840A1 (en) 2014-09-18
CY1120742T1 (el) 2019-12-11
EP3441390A1 (en) 2019-02-13
EP2820013A1 (en) 2015-01-07
LT2820013T (lt) 2018-10-25
CA2866113C (en) 2020-05-12
US8987318B2 (en) 2015-03-24
AU2013225840B2 (en) 2017-11-23
SI2820013T1 (sl) 2018-11-30
KR20140146089A (ko) 2014-12-24
EP2820013B1 (en) 2018-07-11
EP2820013B9 (en) 2019-01-09
TR201815013T4 (tr) 2018-11-21
KR102112879B1 (ko) 2020-05-19
ES2691079T3 (es) 2018-11-23
CN104284893B (zh) 2017-04-19
IL234413B (en) 2018-05-31
HK1206030A1 (en) 2015-12-31
WO2013130892A1 (en) 2013-09-06
US20150152094A1 (en) 2015-06-04
SG11201405378VA (en) 2014-09-26
RS57863B1 (sr) 2018-12-31
DK2820013T3 (en) 2018-10-29
JP6800922B2 (ja) 2020-12-16
JP2015512883A (ja) 2015-04-30
HUE040231T2 (hu) 2019-02-28
MX361349B (es) 2018-12-04
CN104284893A (zh) 2015-01-14
US20150045399A1 (en) 2015-02-12
BR112014021515A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
MX2017014375A (es) Moduladores del ccr2.
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: HERITAGE HD, LLC

FG Grant or registration